Pharmacological CHD1L inhibition with OTI-611 similarly enhances PARPi efficacy, promoting PARP1/2 trapping and PARthanatos in both BRCA-mutant and BRCA-wildtype breast cancer models [74, 76]. Here, CHD1L is linked to breast carcinoma.